InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,607.60
(
-0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.32
(
-0.66%
)
Bitcoin
62,426.50
(
0.15%
)
Post# of 251749
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

hptaxis

Send PM Follow Ignore
Followers 16
Posts 1775
Boards Moderated 0
Alias Born 08/05/2008

hptaxis

Re: None

Tuesday, 12/04/2018 8:15:07 AM

Tuesday, December 04, 2018 8:15:07 AM

Post# of 251749
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
https://investors.revance.com/news-releases/news-release-details/revances-rt002-demonstrates-unprecedented-efficacy-and-duration

– In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines –
– The median time to return to baseline glabellar line severity was 28 weeks –
– RT002 represents the first long-acting neuromodulator, allowing for two or fewer treatments per year –
– Revance announces new trials in forehead lines and lateral canthal lines (crow’s feet) –
– Revance to host conference call at 8:30 am ET today –

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up